IPO Listed
Generate Biomedicines IPO
US$400m raised
Lodged 26 Feb 2026 · NASDAQ: GENB · US$16.00 cash per share
Advisers
Lead managers
- Bookrunner
- Underwriter
- Goldman Sachs
(co)Morgan Stanley
(co) - Legal adviser
- Issuer
- Generate Biomedicines
- Issuer based in
- United States
- Listed
- 2 Mar 2026
- Sector
- Biotech
- Tags
- Biotech, AI, Drug Development
In the league tables
Similar deals
- METiS TechBio IPO May 2026 · Biotech
- Kardigan IPO Jun 2026 · US$400m · Biotech
- Korsana Biosciences placement Apr 2026 · US$380m · Biotech
- Braveheart Bio IPO Aug 2026 · US$383m · Biotech
- Eikon Therapeutics IPO Feb 2026 · US$381m · Oncology
Sources
- Feb 2026 Guggenheim Securities: Joint Bookrunner to Generate Biomedicines on its Initial Public Offering guggenheimsecurities.com
- 26 Feb 2026 Generate Biomedicines, Inc. pipersandler.com
- 27 Feb 2026 Final IPO prospectus (424B4), Generate Biomedicines, Inc. sec.gov
- 4 Mar 2026 Goodwin Advises Generate Biomedicines, Inc. on the Closing of its $400 Million Initial Public Offering goodwinlaw.com


